

ARPA-H Sprint for Women's Health Frequently Asked Questions (FAQs)

Last Updated: April 9th, 2024

Note: This document is subject to change

Solution Summary Phase

Q: What is the overall goal of the Sprint for Women's Health?

A: The Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women's Health intends to fundamentally change the trajectory of women's health care research and radically accelerate the next generation of discoveries. Learn more here:

<https://sprint.investorcatalysthub.org/request-for-solutions/>.

Q: Are there priority research areas?

A: The RFS invites Solution Summary submissions on six topics of interest in women's health for either the Spark or Launchpad track. Please note that submissions outside of topics listed below will not be considered at this time. Learn more about the topic areas here:

<https://sprint.investorcatalysthub.org/request-for-solutions/>.

Q: How were the topic areas selected?

A: ARPA-H Program Managers developed topic areas informed by an ARPA-H executive convening and problem formulation process on women's health.

Q: What if I have an idea that doesn't fit into the topic areas?

A: If your idea doesn't fit into Topic 1-5, submit to Topic 6: WILD CARD: Revolutionary Breakthroughs in Women's Health.

Q: Do we have to declare if we are applying for Spark or Launchpad?

A: Yes. You will be required to select Spark or Launchpad for your topic area in your Solution Summary submission.

Q: Are solutions focused on diagnostics, therapeutics, generative AI, and/or care delivery models eligible?

A: Yes, please refer to the topic description for further information. Evaluation of all Solution Summaries will be based on relevancy to the proposed topic area in women's health and Technical Merit, for launchpad submissions only, additionally commercial viability will be evaluated as well. Prioritization will be based on these criteria. Overlap in federal funding will be addressed.

Q: Will there be prioritization for solutions that prioritize women's health conditions that have less federal research relative to the burden of disease?

A: Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in women's health, Technical Merit, and for launchpad submissions only, Commercial Viability. Prioritization will be based on these criteria. Overlap in federal funding will be addressed.

Q: Can ARPA-H map development milestones to the Technology Readiness Levels (TRL) to help us determine if we should apply to Spark or Launchpad?

A: ARPA-H will not map development milestones. Please refer to the TRL document [here](#). It is up to the proposers to determine if they should apply to Spark or Launchpad track.

Q: How do you select a funding track if you expect a project to begin at one TRL and end at another?

A: It is up to the proposers to determine if their solution fits within the Spark or Launchpad track. Spark awards will be approximately \$3M and Launchpad awards will be approximately \$10M.

Q: How do you select a funding track if the solution fits in multiple TRLs?

A: It is up to the proposers to determine if their solution applies to the Spark or Launchpad track.

Q: Does a Launchpad solution need to be market-ready in a certain period of time to receive funding?

A: Launchpad awards aim to accelerate later stage transformative health solutions reaching the public. The Launchpad performers will be at a higher Technology Readiness Level (TRL) stage (5+) in the specific topics of interest in Women's Health where they still require technical development but are poised to impact health outcomes in the short term. The period of performance for both Launchpad and Spark are expected to be 24 months.

Q: In past Proposer's Days there have been defined key performance indicators and deliverables, which helped to determine project scope and budget. What are the expected key performance indicators and deliverables for each funding track?

A: Please refer to each topic to determine what will be the key performance indicators. During the pitch phase the proposer will provide a more in-depth approach to key performance indicators and deliverables for each funding track and topic. Those proposers invited for IC&N phase will further define the key performance indicators.

Q: Our solution seeks to apply technology in a novel way. Are implementation solutions eligible for funding?

A: Yes.

Q: Do we need to include preliminary results in the Solution Summary?

A: All topics will be evaluated against the criteria outlined in RFS Section 4, and 5. Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in Women's Health, Technical Merit, and Commercial Viability only for Launchpad track.

Q: How do you define "core competencies and levels of effort" on the Solution Summary cover page?

A: A core competency is a particular set of skills, knowledge, abilities, and resources that collectively distinguish the team and enable it to excel in its specific area of pursuit. Level of effort for individual team members refers to the amount of time and resources that each member invests in carrying out their responsibilities for the proposed effort.

Q: What is your preferred format for the Solutions Summary?

A: ARPA-H has provided a template for the Solutions Summary. Please see the amended Request For Solutions and templates in "Key Documents" [here](#). This is currently in a word doc format but when submitting you are REQUIRED to turn this into a PDF.

Q: Can we include figures, tables, and data in the solution summary? Can we include citations and do they count towards the page limit?

A: Yes you can include figures, tables and data in the solution summary. However, it is recommended to use figures and data only to convey key points, as the proposer only has three pages for their solution summary. Any citation list of references can be added as an appendix and will not count towards three page maximum.

Q: Can we include references and citations in my solution summary?.

A: Yes, a citation list of references can be added as an appendix and will not count towards three page maximum. However, letters of support are not required.

Q: Does the "Pricing" Evaluation Criteria refer to the project cost or the solution cost? Is a ROM required for the Solution Summary Phase?

A: The "Pricing" Evaluation Criteria refers to the Rough Order of Magnitude (ROM) pricing that describes the basic unbundled prices. It shall encompass all known costs associated with the proposed effort. The ROM will be evaluated as affordable /non-affordable (if provided or if not). Please see the amended Request For Solutions in "Key Documents" [here](#); ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided.

Q: Can a prime apply to both Spark and Launchpad to develop different products that fit into a single topic (e.g., Topic 1)?

A: A proposer or team can submit to multiple topics. However, only one Solution Summary can be submitted per PI/Lead per topic.

Q: What's the desired end stage for a Spark project, for e.g., demonstrate proof of concept or complete design and development phase?

A: The Spark awards will focus on transformative early-stage research efforts (TRLs 1-4). Please refer to the TRL document [here](#). It is up to the proposers to determine if they should apply to Spark or Launchpad track

Q: For a Launchpad product, is it acceptable to take an FDA cleared test and propose manufacturing innovation activities that will reduce the cost per device to enable uptake in the home?

A: Yes, for Launchpad track we also evaluate Commercial Viability in addition to Relevancy to proposed topic and Technical Merit.

Q: Should community members be part of the design of the study or involved in the development of the intervention/innovation?

A: Any mix of institutions/organizations is allowed.

Q: What is meant by "models" in Topic 03?

A: Development of innovative living and digital female-specific models platforms, which are tailored and optimized to study women's health issues. Some examples of these solutions

would be:

- Develop healthy models that emulate the response of a tissue, organ, or organ system that is critical for women's health.
- Develop disease models that accurately mimic how diseases manifest and progress in females, considering conditions that predominantly affect women or present differently in women compared to men.
- Facilitate an improved understanding of disease heterogeneity based on sex and gender.
- Include novel features, functions, and design choices that improve the ability to predict the response of women to interventions.

Q: For Topic 04, would the white paper need to address all of the three components: novel diagnostics, innovative therapies, platform development? Can the white paper address two out of the three components (i.e., innovative therapies and platform development).

A: The Solution Summary can include any of those three components. The Solution summary should be relevant to the proposed topic in women's health and will be evaluated based on how the Solution Summary addresses the Heilmair Questions 1-4. Please see the RFS for more details.

Q: For Topic 05, would an optimal proposal include clinical studies for multiple conditions (i.e. rheumatoid arthritis, and migraines)? Clinical studies for multiple pain types (i.e. nociceptive pain, neuropathic pain, pain due to central nervous system sensitization)? Would a proposal benefit from evaluating pain measurement and management in an ED setting?

A: Submissions may include one or more conditions and the clinical setting is up to the responder to outline in their proposal. Evaluation of Solution Summaries will be based on Relevancy to the proposed topic, Technical Merit, and Commercial Viability for Launchpad only.

Q: For Topic 06, what topics are acceptable?

A: It is up to the proposers to determine which topic their solution fits under. Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in women's health, Technical Merit, and Commercial Viability Only for Launchpad track

Q: For Topic 6, what is the criteria of a solution that is not well-supported by private and public investment?

A: All topics will be evaluated against the criteria outlined in RFS Section 4, and 5.

Q: Is it OK to address more than one health topic as a part of the proposal? For example, a project that covers Topic 03 and Topic 06.

A: Yes, you can submit a Solution Summary that may include aspects from multiple topic areas. However, each lead can submit only Solution Summary per topic area.

Q: Do we need to include the final market target price for the technology at this stage?

A: For Launchpad track ONLY, we will evaluate for commercial viability.

Q: If we go for the Launchpad track but the reviewers decide an application is more suitable for the Spark track, is the same application possibly considered for Spark when initially applying for the Launchpad?

A: No, Launchpad submissions will be evaluated as a Launchpad submission and will not be considered for Spark.

Q: Is it required to focus the Solution Summary on a single target market or can it include multiple target markets? Is there a minimum target market size?

A: It is up to the proposers to determine the appropriate target market and size for their proposed solution, including whether it is a single or multiple target market.

Q: Can I meet with ARPA-H and/or an ARPA-H PM to discuss our proposed team and solution prior to submission?

A: No, we will not provide feedback on solution summaries or pitches prior to submission.

Q: Is there a link to the Women's Health Proposer Day recording and slides?

A: Virtual Proposers' Day was held on Wednesday, March 6, 2024. ARPA-H provided an overview of the Sprint for Women's Health RFS, the application process, and details of the six women's health topics. [Watch the event recording](#) and [access the event slides](#).

BIDS Submissions

Q: Does the PI or is the Authorized Organizational Representative (AOR) of the institution register on the BIDS platform?

A: It can be either the PI or the AOR as long as the person has appropriate organizational authority to submit.

Q: Should an organization only register once as a submitter in BIDS or may one organization have multiple submitters?

A: Each submitter must register for their own submitter account. Please see instructions for the BIDs submission in "Key Documents" [here](#).

Q: Can you also clarify the difference between the "Tech POC" and "Contract POC" on the IC Hub BIDS Portal?

A: Tech POC Identifies who will be the technical point of contact. Contract POC Identifies who will be the contracts point of contact. Please watch the BIDs submitter training [here](#).

Q: Can I edit my application once it's been submitted?

A: Yes. Please see instructions for the BIDs submission in "Key Documents" [here](#).

Pitch Phase

Q: When will applicants be informed that they have made it to the pitch phase?

A: Following the solution summary evaluation phase applicants will be informed. The pitch phase will take place between May - July 2024.

Q: Who are the reviewers? Do they have content area expertise? A general scientific background? Or are they potentially from diverse backgrounds including non-scientific sectors (finance, business, etc)

A: The reviewers are the PMs. PMs are also supported by ARPA-H contracted eXpert in Residence (XIR)s, support contractors, SETA contractors, or other subject matter experts (to include NIH-approved submissions readers and content area-specific experts).

Q: Will an offeror be allowed to update its ROM pricing if it makes it to the Invitation for Collaboration & Negotiation?

A: Offerors will be asked to submit a full cost proposal if invited to IC&N.

Q: Does the PI who submits the solution summary have to be the same person who presents the pitch? Or can it be a different member of the team?

A: The presenter does not need to be the lead PI and may delegate responsibilities to the members of their team.

Q: Will the pitch take place in-person or virtually?

A: The pitch presentations will be conducted in person.

Q: What will be negotiated after the pitch phase?

A: Refer to RFS Section 4.1.3 for what will be negotiated.

Awards and Eligibility

Q: How many solutions will be funded under the Sprint for Women's Health and each funding track or topic area?

A: We seek to fund \$100M in awards. We do not have a defined number of awards by funding track or topic area.

Q: Will early submissions be prioritized?

A: No, all submissions will be reviewed after the submission deadline.

Q: When is the deadline for submissions?

A: All submissions must be completed before Monday, April 15th at 12pm ET.

Q: Will each funding track fund IRB studies on human subjects?

A: Yes. Pay special attention to the requirements concerning Human Subjects and use of Vertebrate Animals.

Q: Do I have to be a member of SAM.gov to be eligible to apply? Do I need to have a Unique Entity Identifier (UEI) when applying?

A: No, it is not required to have a SAM.gov Unique Entity Identifier (UEI) to apply, however, to be eligible for AWARD proposers are required to have an UEI and be registered in SAM.gov.

Q: Do I need a CAGE number to apply?

A: No, it is not required to have a CAGE number to apply, however, to be eligible for AWARD proposers are required to have CAGE Code.

Q: Do you have to be a US-based company to be eligible? Do you have to partner with US-based companies to be eligible?

A: No. You do not have to be a US-based company.

Q: Are non-profit organizations, for-profit organizations, government agencies (e.g., state health department), and start-ups eligible to apply?

A: Non-profit organizations, for-profit organizations, and start-ups are eligible to apply. Government Agencies are not eligible.

Q: Am I able to apply to the multiple government funding opportunities for my solution (e.g., ARPA-H's Open BAA and Sprint for Women's Health)?

A: Yes.

Q: Am I eligible to receive funding if I already receive other government funding (e.g., NIH) for my solution?

A: Yes. Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in women's health, Technical Merit, and Commercial Viability Only for Launchpad track. Prioritization will be based on these criteria. Overlap in federal funding will be addressed.

Q: Can NIH Intramural investigators apply to the Sprint for Women's Health?

A: Submitting organizations are also known as "prime performers". The prime performer can propose Government Entities as sub performers only if they provide a statement from the Government Entity's direct supervisor or agency ethics attorney, stating the individual(s) have no ethical challenges receiving compensation for their services as a Federal employee and have no Conflicts of Interest to support the prime performer. If a Government entity is interested in working directly with the Government team supporting this program, please contact womenshealth@arpa-h.gov.

Q: Do you have to be a member of the Investor Catalyst Hub to receive funding?

A: Yes. If invited to Pitch, proposers must apply to become an Investor Catalyst (IC) Hub Spoke, if they haven't already. If selected for award, proposers must have their spoke approval to receive award. You can apply to be an Investor Catalyst Hub member here: <https://investorcatalysthub.org/spoke-network/>.

Q: Will any priority be given for women owned, veteran owned, or service-disabled veteran owned, or other minority owned companies?

A: Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in women's health, Technical Merit, and Commercial Viability Only for Launchpad track. Prioritization will be based on these criteria.

Q: What is the solutions library? Are the solutions in the solutions library publicly available?

A: The solutions library is a confidential repository. ARPANET-H will maintain submissions with technical merit to speed up the review and approval for future funding opportunities proposers may be applicable to receive. The Solutions Library is not publicly available.

Q: Can we request not to publicly list our submissions?

A: The information provided in the submission is sensitive. It will not be publicly available.

Q: If awarded, what is the contract timeline for each funding track?

A: Awards are anticipated by the end of the Government Fiscal Year (September 30, 2024).

Q: If awarded, is there expectation that the awardee will match a percent of the funding received?

A: While there is no requirement for cost-share, proposers are reminded Sparks are approximately \$3M and Launchpads are approximately \$10M.

Q: If awarded, how are payments made and what is the payment cycle? Do awardees need to be able to cover upfront costs?

A: Each awarded project will have a negotiated Milestone Payment schedule.

Q: If awarded, are there salary caps? If so, what is the salary allowance for the project lead during the project time frame?

A: Yes, refer to RFS Section 4.2 Item 5 "Salary Limitation" for Salary Cap information.

Q: If awarded, does this funding qualify as R&D that must be amortized over five years?

A: ARPA-H will not dictate this as it is applicable to the business dealings of each proposer.

Q: If awarded, how is intellectual property (IP) impacted? Will the NIH have ownership or rights to any of the research that is funded through ARPA-H?

A: ARPA-H intends to negotiate the requisite IP rights prior to each award.

Q: Can an individual submit a solutions summary and Spoke Network membership application

or do you need to be part of a larger organization?

A: Yes, but to be eligible for award proposers are required to have a Unique Entity Identifier (UEI) and be registered in SAM.gov as well as a Commercial and Government Entity (CAGE) Code.

Q: Is this funding mechanism a cooperative agreement or a contract?

A: The funding mechanism will be an Other Transaction (OT) Agreement (which is a contract).

Q: Will the resulting award be a firm fixed Price or Cost?

A: Pricing structure to be determined during IC&N.

Q: If we receive a Spark award, would this impact a new/early investigator status with the NIH?

A: No, but proposers should check regulations with NIH for their submission process.

Q: Is it permissible to allocate a portion of the awarded funds for research support in a location outside of the United States, such as in collaboration with an institution in Australia?

A: ARPA-H anticipates that teaming will be necessary to achieve the goals of the program, thus we encourage perspective proposers to form teams with varied technical experience to submit a Solution Summary.

Q: Is it possible to subcontract national lab employees for a portion of the project?

A: Only non-government entities/teams may submit a Solution Summary and receive funding.

Q: Are we permitted to allocate funds for acquiring data, such as recruiting patients and covering expenses for their genome sequencing?

A: ARPA-H will fund allowable costs. Pricing structure to be determined during IC&N.

Q: Are both prime and subcontractors required to be members of the Investor Catalyst Hub?

A: Only the prime is required but we encourage all partners to join the Investor Catalyst Hub.

Q: How does ARPA-H handle Facilities and Administrative (F&A) costs, including those related to subcontractors? Will participants need a DHHS agreement similar to the one mandated for NIH funding?

A: F&A costs are indirect costs commonly allowable under Other Transactions. Negotiation of all costs will be conducted during the IC&N phase.

Q: Does ARPA-H have any restrictions on funding certain budget categories? (e.g. patenting expenses, legal fees, etc.)

A: ARPA-H will fund allowable costs. Pricing structure to be determined during IC&N.

Q: In addition to technical and R&D aims and milestones, does this funding mechanism allow for clinical validation trials, including FDA approval studies?

A: Yes, those activities are allowable, however the allowable costs will be negotiated during IC&N.

Q: Does this funding mechanism allow development of reimbursement and Centers for Medicare & Medicaid Services (CMS) payment strategies?

A: Yes, those activities are allowable, however the allowable costs will be determined during IC&N.

Q: Can we continue to use the remaining funds at the end of the 2-year period for clinical follow-up for a clinical study (similar to the no-cost extension period for NIH grants)?

A: During the pitch phase we expect the proposer to provide a Rough Order of Magnitude (ROM) of cost and timeline of how funds will be expended. No cost extensions may be granted but those funds will be used for the proposed work.

Q: If granted the award, is the awardee permitted to sell the product during the period of performance?

A: Sprint for Women's Health aims to foster transformative R&D efforts from early-stage research to later-stage development.

Q: Do sub awardees have to provide a cost breakdown for each of the cost categories in the ROM budget, same as the prime, or can a Subawardee budget be one lump sum only in the prime budget?

A: Subawardee's costs may be included in the prime budget for the Solution Summary and Pitch Phase. Please see the amended Request For Solutions; ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided.

Q: Will you accept proposals that are longer than 24 months in scope? (i.e. 36 months)?

A: The expected period of performance will be 24 months.

Q: For university start-ups, can the funds be divided to support both the work completed through the university and the work completed by the new entity separately?

A: Pricing structure to be determined during IC&N.

Q: Is ARPA-H only interested in investing in advances with a commercial component or would you consider research of a treatment solution?

A: Sprint for Women's Health aims to foster transformative R&D efforts from early-stage research to later-stage development.

Q: Do the Spark or Launchpad budget and awards include and cover direct and indirect costs?

A: Please see the amended Request For Solutions in "Key Documents" [here](#); ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided.

Q: Does ARPA-H have an indirect cost rate that must be followed or can we use the indirect rate allowed at our institution?

A: Please see the amended Request For Solutions in "Key Documents" [here](#); ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided. Proposed indirect rates should be consistent with the institution's approved rates.

Q: Will our NICRA be accepted as our indirect cost rate?

A: Yes, with the supporting memorandum. Please see the amended Request For Solutions in "Key Documents" [here](#); ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided.

Q: Is there a limit for indirect costs for small businesses? If so, Is there a negotiated or safe indirect rate similar to NIH?

A: No, proposed indirect rates should be consistent with the institution's approved rates. Please see the amended Request For Solutions; ROM is no longer required for Solution Summary Phase. It will be required for Pitch Phase and Pitch templates will be provided.

Q: Does the initial submission of the RFS require approval and sign off by my university or can

that be done at a later stage?

A: Please refer to your organization guidance/policy on submissions. ARPA-H expects that proposers invited to negotiate will include a representative from the organization that is authorized to bind the organization into contract with the Investor Catalyst Hub.

Q: On the title page, are the required field headings needed, or just the response to the heading? e.g., "Topic Area #: Women's Health Topic 01" OR just "Women's Health Topic 01"

A: The cover page should include all information outlined under RFS Section 5.1.

Q: Can the contact address be a PO Box?

A: Yes, however, to be eligible for award, proposers are required to have an UEI/CAGE and be registered in www.SAM.gov.

Q: We are applying for this proposal and need to add your organization to our system. Can you provide ARPA-H's address and agency ID?

A: Advanced Research Projects Agency for Health (ARPA-H); 1 Center Drive Bethesda, MD 20892; Agency ID 75N992.

Teaming

Q: Do you need to have a specific partner(s) from industry, academia, etc.?

A: No.

Q: Can one group be part of multiple Solution Summaries?

A: Yes, one group can be part of multiple Solution Summaries, however each lead can only submit one Solution Summary per topic.

Q: Is there a limit to how many institutions can team?

A: No, there is no limit on how many institutions can team.

Q: Will you establish teams for us?

A: No, it is your responsibility to reach out to other organizations you are interested in teaming with. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a Solution Summary to the Sprint. To facilitate this process, we have created a [teaming page](#) where prospective performers can share their profiles and learn more about other interested parties.

Q: Will you facilitate a request for collaboration with public health departments?

A: No, it is your responsibility to reach out to other organizations you are interested in teaming with. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a Solution Summary to the Sprint. To facilitate this process, we have created a [teaming page](#) where prospective performers can share their profiles and learn more about other interested parties.

Q: Can the same proposer or proposer team submit a Solution Summary to multiple topics?

A: Yes, a proposer or team can submit to multiple topics. However, only one Solution Summary can be submitted per PI/Lead per topic.

Q: Can an organization join the Investor Catalyst Hub to support solutions even if we do not plan to submit our own solutions?

A: Yes, we invite you to apply to be an Investor Catalyst Hub member here: <https://investorcatalysthub.org/spoke-network/>.

Q: Is it possible to do the teaming among the selected teams after the pitching?

A: The [teaming page](#) will remain open through the solicitation period. It is your responsibility to reach out to other organizations you are interested in teaming with.

Q: Is teaming mandatory or optional?

A: Optional.

Q: Can I team with a Launchpad applicant as a Spark applicant?

A: Yes, one group can be part of multiple Solution Summaries, however each lead can only submit one Solution Summary per topic.

Q: Can I edit my Teaming profile information once I've submitted?

A: Yes, an organization should submit 1 teaming application per institution, but they may edit their submissions. Once you've completed your Teaming Profile, your confirmation email will include a link that will allow you to log back into your existing profile to update and make any desired changes.

Q: Can I partner with an FFRDC or someone who works at one?

A: No, FFRDC's are not eligible to be teaming partners. Further, Government Agencies are not eligible to be teaming partners.

Q: Does the Team Lead need to be a full-time employee of the proposing institution/organization?

A: The construct of the team for the proposing institution/organization is a business decision.

Q: Do the key personnel and team need to be specifically named people or can these be placeholder roles that would be filled once we find out if we receive funding?

A: Initial placeholders are acceptable for personnel.

Q: Can the teams have two leaders (i.e. co-PI's)?

A: The construct of the team for the proposing institution/organization is a business decision.

Q: If we are proposing a solution in collaboration with another partner, where both parties are developing related, but complementary, and distinct activities, can we apply for separate funding to support the work?

A: Yes, one group can be part of multiple Solution Summaries, however each lead can only submit one Solution Summary per topic. Evaluation of Solution Summaries will be based on Relevancy to the proposed topic in women's health, Technical Merit, and for launchpad submissions only Commercial Viability.

Q: What are the key differences between sub awardees compared to partners or collaborators?

A: A sub-awardee is considered to be the "prime performer" on the sub award. Sub-awardees might engage partners or collaborators to be members of the sub-awardee's team however, the sub-awardee is the entity responsible for the performance of the project.

Q: Are subcontractors allowed to partner with multiple applicants?

A: Yes, a subcontractor may team with multiple partners across different initiatives.

Q: Can we add collaboration and partners (sub awardee) after the solution summary submission (pitching) phase and if selected, for I&CN phase?

A: Yes, you may add additional partners throughout the duration of the program work. Further details will be provided to award recipients on how to select and add future partners.

Q: Can a team contain member(s) that are federal employees that work in a national lab?

A: Only non-government entities/teams may submit a Solution Summary and receive funding.

Q: Can we team with companies that are not on the Teaming list?

A: Yes, you may choose Teaming partners who are not listed.